BioLineRX Ltd. (IL:BLRX)
TASE:BLRX
Top Page
Bioline Rx
(TASE:BLRX)
Select Model
Select Model
Rating:48Neutral
Price Target:
1.50
▲(0.00% Upside)
Action:ReiteratedDate:03/26/26
The score is held down primarily by weak financial performance (ongoing losses, cash burn, and sharp TTM revenue contraction) and a bearish technical setup (below major moving averages with negative MACD). The earnings call provides some support via multi-year cash runway and pipeline/JV progress, but valuation is constrained by a negative P/E and no dividend.
Positive Factors
Strategic joint venture
The Hemispherian JV spreads late‑stage development cost and scientific risk while leveraging partner expertise. BioLineRx holds an economic stake (initial 40% with potential to increase), preserving upside while reducing capital intensity and accelerating GLIX1 development timelines.
Negative Factors
Persistent cash burn
Consistent negative operating and free cash flow indicates the business cannot self‑fund development. Over months this forces reliance on external capital, partnerships or milestone financings, increasing dilution and risk that programs slow if non‑dilutive funding does not materialize.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic joint venture
The Hemispherian JV spreads late‑stage development cost and scientific risk while leveraging partner expertise. BioLineRx holds an economic stake (initial 40% with potential to increase), preserving upside while reducing capital intensity and accelerating GLIX1 development timelines.
Read all positive factors
Bioline Rx (BLRX) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪33.94M
Dividend YieldN/A
Average Volume (3M)4.64M
Price to Earnings (P/E)―
Beta (1Y)0.33
Revenue Growth-42.69%
EPS Growth88.04%
CountryIL
Employees28
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,610,814,500
10 Day Avg. Volume5,813,402
30 Day Avg. Volume4,637,561
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.68
Price to Sales (P/S)9.69
P/FCF Ratio-1.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)₪1.50M
Bioline Rx Business Overview & Revenue Model
Company Description
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phas...
How the Company Makes Money
BioLineRx primarily makes money through (1) collaboration and licensing arrangements and (2) product-related revenue where it has commercialization rights. Under collaboration/licensing deals, the company may receive upfront payments, milestone pa...
Bioline Rx Earnings Call Summary
Earnings Call Date:Nov 24, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:May 27, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted BioLineRx's strategic joint venture for glioblastoma treatment and robust financial health. However, decreased R&D and marketing expenses indicate reduced operational activities following out-licensing agreements. The sentiment is balanced with significant potential in new cancer treatments offset by reduced operational scope.Positive Updates
Joint Venture with Hemispherian
BioLineRx established a joint venture with Hemispherian to develop GLIX1, an innovative molecule for glioblastoma treatment. This partnership leverages BioLineRx's clinical and regulatory success with Hemispherian's expertise in DNA damage response research.
Negative Updates
Decreased Research and Development Expenses
R&D expenses decreased from $2.6 million to $1.7 million year-over-year, primarily due to a decrease in headcount and lower expenses related to motixafortide after out-licensing.
Read all updates
Q3-2025 Updates
Positive
Negative
Joint Venture with Hemispherian
BioLineRx established a joint venture with Hemispherian to develop GLIX1, an innovative molecule for glioblastoma treatment. This partnership leverages BioLineRx's clinical and regulatory success with Hemispherian's expertise in DNA damage response research.
Read all positive updates
Company Guidance
During the BioLineRx Third Quarter 2025 Financial Results Conference Call, the company provided guidance on several key initiatives and financial metrics. BioLineRx highlighted its joint venture with Hemispherian to develop GLIX1, a first-in-class oral small molecule for glioblastoma treatment, with plans to initiate a Phase I/IIa trial in early 2026 and anticipate data from the Phase I portion in the first half of 2027. The company holds a 40% stake in the JV, anticipated to increase to 70% with further investment. Financially, BioLineRx reported $25.2 million in cash and equivalents, sufficient to fund operations into the first half of 2027, and generated $0.4 million in royalty revenue from APHEXDA sales. The call also covered the ongoing development of motixafortide, with a Phase IIb trial in pancreatic cancer and potential expansion into sickle cell disease.Bioline Rx Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
44
Neutral
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.28M | 28.94M | 4.80M | 0.00 | 0.00 |
| Gross Profit | 462.21K | 19.68M | 1.11M | 0.00 | 0.00 |
| EBITDA | -10.57M | 3.92M | -57.09M | -28.50M | -24.07M |
| Net Income | -1.27M | -9.22M | -60.61M | -20.75M | -28.14M |
Balance Sheet | |||||
| Total Assets | 40.91M | 38.91M | 63.92M | 76.38M | 81.39M |
| Cash, Cash Equivalents and Short-Term Investments | 20.88M | 19.56M | 42.99M | 51.08M | 57.13M |
| Total Debt | 10.15M | 15.04M | 11.59M | 12.32M | 4.65M |
| Total Liabilities | 17.56M | 25.45M | 50.70M | 25.54M | 13.30M |
| Stockholders Equity | 18.20M | 13.46M | 13.22M | 50.84M | 68.09M |
Cash Flow | |||||
| Free Cash Flow | -8.77M | -43.93M | -22.91M | -26.56M | -23.67M |
| Operating Cash Flow | -8.74M | -43.87M | -22.61M | -26.24M | -23.57M |
| Investing Cash Flow | -9.25M | 29.37M | 1.44M | 4.01M | -38.22M |
| Financing Cash Flow | 9.62M | 20.66M | 15.06M | 20.44M | 57.75M |
Bioline Rx Technical Analysis
Negative
1.50
Price Trends
1.46
Negative
1.57
Negative
1.93
Negative
Market Momentum
-0.06
Positive
44.61
Neutral
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:BLRX, the sentiment is Negative. The current price of 1.5 is above the 20-day moving average (MA) of 1.37, above the 50-day MA of 1.46, and below the 200-day MA of 1.93, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 44.61 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IL:BLRX.
Bioline Rx Risk Analysis
Bioline Rx disclosed 43 risk factors in its most recent earnings report. Bioline Rx reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Bioline Rx Peers Comparison
UnderperformOutperform
Sector (51)
IL:BLRX
Bioline Rx
1.30
-0.30
-18.75%
IL:XTLB
Xtl Bio
2.00
-2.30
-53.49%
IL:CBI
Clal Biotech
32.50
3.60
12.46%
IL:CANF
Can Fite Bio
522.40
520.60
28922.22%
IL:BOLT
Biolight
270.00
-359.40
-57.10%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.